Investors are watching the major index providers to see when they might add shares of SpaceX to their indexes. Some of the ...

CRISPR Therapeutics achieved approvals for Casgevy in SCD and TDT, boosting patient uptake. Beam is advancing base-editing therapies, with BEAM-101 showing promise in sickle cell disease. CRSP shares ...

Its revolutionary CASGEVY treatment could be a sign of what's to come.

CRISPR Therapeutics CRSP reported a second-quarter 2025 loss of $2.40 per share, which was wider than the year-ago period’s loss of $1.49. The increased loss was attributable to the payment of $96.3 ...

CRISPR Therapeutics CRSP is expected to report third-quarter 2025 earnings later this week. The Zacks Consensus Estimate for quarterly sales is pegged at $6.71 million, while that for earnings is ...

CRISPR Therapeutics AG (NASDAQ:CRSP) is one of the most shorted mid-cap and small-cap stocks to buy now. On May 27, research firm Citizens reiterated a Market Perform rating and a $60 price target on ...

In late 2023, the company had a breakthrough when it received approval for CASGEVY. This is the first gene editing treatment of its kind to be approved. CASGEVY addresses sickle cell disease (SCD) and ...

Crispr Therapeutics Ag (NASDAQ:CRSP) is one of the Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy. Biotech company Crispr Therapeutics Ag (NASDAQ:CRSP) shares are up 16% over the past 12 months.

CRSP reported Q2 loss of $2.40 per share, impacted by $96.3M Sirius collaboration expense. Vertex recorded $30.4M in Q2 Casgevy sales, with over 75 treatment centers activated globally. CRSP ended ...